Oxytocin
Pitocin (oxytocin) is a protein pharmaceutical. Oxytocin was first approved as Oxytocin on 1982-01-01. It is used to treat postpartum hemorrhage in the USA. The pharmaceutical is active against oxytocin receptor. In addition, it is known to target vasopressin V1a receptor, vasopressin V2 receptor, and vasopressin V1b receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Pitocin (generic drugs available since 2013-02-13, discontinued: Syntocinon)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
pitocin | New Drug Application | 2021-06-15 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G02: Other gynecologicals in atc
— G02A: Uterotonics
— G02AC: Ergot alkaloids and oxytocin incl. analogues, in combination
— G02AC01: Methylergometrine and oxytocin
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01B: Posterior pituitary lobe hormones
— H01BB: Oxytocin and analogues
— H01BB02: Oxytocin
HCPCS
Code | Description |
---|---|
J2590 | Injection, oxytocin, up to 10 units |
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Wilms tumor | D009396 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | 1 | — | — | 1 |
Furunculosis | D005667 | L02.92 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | OXYTOCIN |
INN | oxytocin |
Description | Oxytocin is a cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour. It has a role as an oxytocic and a vasodilator agent. It is a peptide hormone and a heterodetic cyclic peptide. |
Classification | Protein |
Drug class | oxytocin derivatives |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CSSC[C@@H](C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O |
Identifiers
PDB | — |
CAS-ID | 50-56-6 |
RxCUI | 7824 |
ChEMBL ID | CHEMBL395429 |
ChEBI ID | 7872 |
PubChem CID | 439302 |
DrugBank | DB00107 |
UNII ID | 1JQS135EYN (ChemIDplus, GSRS) |
Target
Alternate
AVPR1A
AVPR1A
AVPR2
AVPR2
AVPR1B
AVPR1B
Organism
Homo sapiens
Gene name
AVPR1A
Gene synonyms
AVPR1
NCBI Gene ID
Protein name
vasopressin V1a receptor
Protein synonyms
Antidiuretic hormone receptor 1a, AVPR V1a, SCCL vasopressin subtype 1a receptor, V1-vascular vasopressin receptor AVPR1A, V1a vasopressin receptor, Vascular/hepatic-type arginine vasopressin receptor
Uniprot ID
Mouse ortholog
Avpr1a (54140)
vasopressin V1a receptor (Q9QYH2)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 43,047 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
294 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more